The Research Consortium announced the release of a new study today that challenges common misconceptions about combination cancer therapies, their cost, and their value. It provides payers, physicians and patients with insight as to how they can avoid wasteful spending on high-cost, low-clinical-value cancer drugs. The concurrent (on- and off-label) use of multiple FDA-approved drugs […]